InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, and micro infarcts. Already patented in the EU, Japan, and…